Stockman Wealth Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13M | Buy |
461,237
+45,961
| +11% | +$1.22M | 1.43% | 31 |
|
|
2025
Q4 | $10.3M | Buy |
415,276
+10,929
| +3% | +$276K | 1.2% | 34 |
|
|
2025
Q3 | $10.3M | Buy |
404,347
+17,627
| +5% | +$435K | 1.28% | 33 |
|
|
2025
Q2 | $9.37M | Buy |
386,720
+30,849
| +9% | +$719K | 1.27% | 33 |
|
|
2025
Q1 | $9.02M | Buy |
355,871
+66,496
| +23% | +$1.74M | 1.34% | 32 |
|
|
2024
Q4 | $7.68M | Sell |
289,375
-9,726
| -3% | -$264K | 1.2% | 30 |
|
|
2024
Q3 | $8.66M | Buy |
299,101
+22,199
| +8% | +$648K | 1.35% | 28 |
|
|
2024
Q2 | $7.75M | Buy |
276,902
+16,815
| +6% | +$463K | 1.36% | 28 |
|
|
2024
Q1 | $7.22M | Buy |
260,087
+39,327
| +18% | +$1.09M | 1.27% | 32 |
|
|
2023
Q4 | $6.36M | Buy |
220,760
+12,088
| +6% | +$365K | 1.27% | 31 |
|
|
2023
Q3 | $6.92M | Buy |
208,672
+10,230
| +5% | +$362K | 1.52% | 26 |
|
|
2023
Q2 | $7.28M | Buy |
198,442
+10,184
| +5% | +$396K | 1.56% | 24 |
|
|
2023
Q1 | $7.68M | Buy |
188,258
+5,445
| +3% | +$235K | 1.72% | 18 |
|
|
2022
Q4 | $9.37M | Sell |
182,813
-6,559
| -3% | -$314K | 2.15% | 13 |
|
|
2022
Q3 | $8.29M | Buy |
189,372
+9,922
| +6% | +$482K | 2.24% | 11 |
|
|
2022
Q2 | $9.41M | Buy |
179,450
+1,996
| +1% | +$102K | 2.4% | 8 |
|
|
2022
Q1 | $9.19M | Sell |
177,454
-1,324
| -0.7% | -$68.7K | 1.91% | 15 |
|
|
2021
Q4 | $10.6M | Sell |
178,778
-10,455
| -6% | -$518K | 2.15% | 5 |
|
|
2021
Q3 | $8.14M | Sell |
189,233
-1,546
| -0.8% | -$68.5K | 1.81% | 9 |
|
|
2021
Q2 | $7.47M | Buy |
190,779
+5,582
| +3% | +$217K | 1.78% | 12 |
|
|
2021
Q1 | $6.71M | Buy |
185,197
+20,971
| +13% | +$745K | 1.87% | 12 |
|
|
2020
Q4 | $6.04M | Buy |
164,226
+1,537
| +0.9% | +$56.4K | 1.85% | 14 |
|
|
2020
Q3 | $5.67M | Sell |
162,689
-1,451
| -0.9% | -$50.9K | 2.07% | 13 |
|
|
2020
Q2 | $5.09M | Buy |
164,140
+5,511
| +3% | +$187K | 1.91% | 15 |
|
|
2020
Q1 | $4.91M | Buy |
158,629
+2,649
| +2% | +$90.3K | 2.18% | 10 |
|
|
2019
Q4 | $5.8M | Buy |
155,980
+3,410
| +2% | +$121K | 2.06% | 13 |
|
|
2019
Q3 | $5.2M | Buy |
152,570
+17,649
| +13% | +$642K | 1.99% | 13 |
|
|
2019
Q2 | $5.54M | Buy |
134,921
+2,201
| +2% | +$87.4K | 2.26% | 10 |
|
|
2019
Q1 | $5.35M | Sell |
132,720
-3,530
| -3% | -$141K | 2.34% | 11 |
|
|
2018
Q4 | $5.64M | Sell |
136,250
-12,724
| -9% | -$528K | 2.7% | 6 |
|
|
2018
Q3 | $6.23M | Sell |
148,974
-4,859
| -3% | -$187K | 2.69% | 5 |
|
|
2018
Q2 | $5.29M | Buy |
153,833
+776
| +0.5% | +$26.5K | 2.42% | 11 |
|
|
2018
Q1 | $5.15M | Buy |
153,057
+5,053
| +3% | +$174K | 2.36% | 10 |
|
|
2017
Q4 | $5.09M | Sell |
148,004
-68
| -0% | -$2.32K | 2.28% | 10 |
|
|
2017
Q3 | $5.01M | Buy |
148,072
+79,833
| +117% | +$2.57M | 2.4% | 8 |
|
|
2017
Q2 | $2.17M | Sell |
68,239
-84,433
| -55% | -$2.66M | 2.17% | 9 |
|
|
2017
Q1 | $4.96M | Buy |
152,672
+11,092
| +8% | +$350K | 2.82% | 3 |
|
|
2016
Q4 | $4.36M | Buy |
141,580
+10,917
| +8% | +$333K | 2.65% | 7 |
|
|
2016
Q3 | $4.2M | Buy |
130,663
+2,184
| +2% | +$73K | 2.6% | 9 |
|
|
2016
Q2 | $4.29M | Buy |
128,479
+5,987
| +5% | +$191K | 3.36% | 6 |
|
|
2016
Q1 | $3.44M | Buy |
122,492
+16,213
| +15% | +$463K | 2.73% | 10 |
|
|
2015
Q4 | $3.25M | Buy |
106,279
+2,058
| +2% | +$64.7K | 2.63% | 10 |
|
|
2015
Q3 | $3.11M | Buy |
104,221
+1,194
| +1% | +$38.3K | 2.68% | 10 |
|
|
2015
Q2 | $3.28M | Buy |
103,027
+220
| +0.2% | +$7.17K | 2.79% | 10 |
|
|
2015
Q1 | $3.39M | Buy |
102,807
+58
| +0.1% | +$1.84K | 2.9% | 8 |
|
|
2014
Q4 | $3.04M | Buy |
+102,749
| New | +$2.95M | 2.6% | 11 |
|
Other funds holding PFE
VCM
VPM
Stockman Wealth Management's PFE Position: Q1 2026 in Review
Stockman Wealth Management increased its Pfizer (PFE) stake by 11% in Q1 2026, buying an estimated $1.22M and bringing the position to 461,237 shares worth $13M. The position accounts for 1.43% of the portfolio, ranked #31.
Stockman Wealth Management first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Stockman Wealth Management held 461,237 shares of Pfizer worth $13M as of Q1 2026.
- Stockman Wealth Management bought 45,961 Pfizer shares in Q1 2026, an estimated $1.22M.
- Pfizer made up 1.43% of Stockman Wealth Management's portfolio in Q1 2026, its #31 holding.
- Stockman Wealth Management first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Stockman Wealth Management's 13F filing for Q1 2026, filed 13 Apr 2026.